Chemist + Druggist is part of Informa PLC


This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

UK reimbursement model a challenge, says Lloydspharmacy parent company

Lloydspharmacy’s parent company has named the UK's reimbursement environment as an area to keep an eye on during 2021.

McKesson’s European division, which includes Lloydspharmacy and the wholesaler AAH, had a "good" last quarter, the company’s CEO Brian Tyler said in response to a question on the "headwinds" – major challenges that could affect growth – for 2021.

But it has faced challenges around “having good line of sight into how the reimbursement mechanisms really play out” within the NHS in particular, Mr Tyler said during a conference call on McKesson’s third quarter 2020 fiscal results last week (February 4).

While he welcomed England's five-year community pharmacy funding deal, Mr Tyler added that the company would “continue to monitor and evaluate… the nuances of the timing and the different mechanisms that make up that framework.”

A McKesson spokesperson told C+D last week (February 4) that McKesson will analyse the “dynamics” of the UK reimbursement environment before it issues its 2021 expectations for the European arm of the business in May.

US challenge

Another challenge to business growth for 2021 is the imminent US election, as McKesson will have to evaluate the politics and policy “that sort of set the framework” for the company, Mr Tyler added during the conference call.

“But to me that's just a normal part of being in healthcare and a normal part of being in this business,” he said.

McKesson reported a 16% profit increase across its European business in the three months leading up to December 31, which it said was “driven in part by lower operating expenses as a result of actions previously taken to rationalise floor footprint and streamline back office functions”.

What do you make of McKesson's statements?

Related Content

Topics



Pharmacy Dispenser/ Technician
Bethnal Green North, London
Salary: Up to £30,000

Apply Now
UsernamePublicRestriction

Register

CD006322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel